Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsReporting bias in medical research - a narrative reviewInsulin resistance in patients with chronic kidney diseaseMBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activationThe imperative to share clinical study reports: recommendations from the Tamiflu experiencePublication of clinical trials supporting successful new drug applications: a literature analysisComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryBenefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adultsCardiovascular outcomes in trials of oral diabetes medications: a systematic reviewNonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsOral anti-diabetic agents for women with pre-existing diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitusOral anti-diabetic agents for women with pre-existing diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitusRosiglitazone for type 2 diabetes mellitusSHRINE: enabling nationally scalable multi-site disease studiesAn oxidized lipid-peroxisome proliferator-activated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesion6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewState Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warningThiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitroNational trends in treatment of type 2 diabetes mellitus, 1994-2007Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesPPARs and the cardiovascular systemConflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journalsEffect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trialNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementLong-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisPharmacogenetic studies update in type 2 diabetes mellitusIs the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes MellitusAssessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversionCardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?Interactions between kidney disease and diabetes: dangerous liaisonsContinued efforts to translate diabetes cardiovascular outcome trials into clinical practiceRecent advances in managing and understanding diabetic nephropathyDiabetes Drugs and Cardiovascular SafetyPeroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis
P2860
Q21144611-17F9E09E-53EE-47A7-8E0E-9FD8235250B2Q21203744-F9867E7D-E40F-4B6A-8384-F45A5D7F02CCQ21285003-E6E7FA8A-D2DD-46C0-9BDD-1682CD81554AQ21342745-6924A1DF-809A-4851-A4C6-77506B91360BQ21563018-033156F1-64B9-4798-9C41-51833A1E8B5FQ21563410-C73D8797-6757-4470-A8A2-F79A37DC656FQ22241134-0696FE99-6379-4DC6-8BB1-2DA8D4D3FFDFQ22241786-7EED393A-D223-4925-BAD3-E6504C170C36Q22242077-0F163092-2476-4087-9BAC-0C46B6B25CEFQ22250879-2DB9394F-9426-42A0-AC8F-D7F9A4B71AA6Q22253058-CFE3B13F-37D6-454B-8D90-46BC2E5D58B2Q22299426-8EF647C5-8548-4C15-A2C1-FD11713D901CQ24234519-BAE6A117-D665-41C6-9E05-0130135E52C7Q24240792-FE17E800-F546-4B22-8F02-C6404F5D1A1EQ24243875-F73D183E-8B28-4EF2-8D85-EA33952EA258Q24288701-1A296ECF-B110-4A29-A7F0-BA7B8745F5EAQ24300694-71B4BCF1-FDA4-40D5-94D6-7D3E298323CEQ24324368-DB8C5376-7E91-4881-AC91-DA6282CE8D3DQ24561401-4E0446C1-68FA-4AA4-A3EC-629BFA45157FQ24604853-7596726D-0811-49B0-BB91-1A4B9E30C70DQ24608491-5537B6A4-6B52-4646-B6C3-A08218A6047BQ24619979-E8A32851-70C9-4EB6-BB3F-6F7BE71D0CA5Q24628988-665C67F2-36E0-44A2-8442-E01FE88592ECQ24632655-0BA6053A-F0D7-43F2-B04F-BC59C199EF16Q24642503-B4AEB7C8-3393-4427-BAF6-9C488368A97BQ24642728-9E78F6A3-A381-4AFD-BD67-70E7FD0F08D7Q24644642-259805A3-3497-479B-89D4-0EA7018D1BBAQ24645513-64F490EB-AC2B-47D2-BADA-76C8C2DD4948Q24649618-DDA4886C-073B-48A9-AC55-AC7F8FC28833Q24655666-86435D56-C6F4-44D4-B141-DC61861DB84CQ26739350-95F6664D-68FF-4C8E-A0E8-F87E4A38D2DBQ26739984-777F5D24-9E04-4B22-B99A-B4D47D878634Q26740006-8A8BDBFD-6328-41B5-95DE-F5E1E9EBB817Q26740171-DD40CFBD-C1AD-4227-BA1B-85F43AC3CC45Q26740247-7FE45E91-2C7C-44AE-8E94-FA7D0B49F4E4Q26740630-8D2C4239-250D-4604-BA98-23091B4C71ADQ26741860-A9D56BE8-006A-4040-BBBC-234F0C7A93A5Q26745900-1FB086A2-BE6A-42E7-82B3-C3F54442F8B7Q26746085-961DDE0A-9F8A-4DA1-B77B-FD14A2F2710EQ26746998-BA8935BF-5F7D-44D0-9D49-B31D75B8F9A3
P2860
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@ast
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en-gb
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@nl
type
label
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@ast
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en-gb
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@nl
altLabel
Effect of rosiglitazone on the ...... ath from cardiovascular causes
@en
prefLabel
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@ast
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en-gb
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@nl
P3181
P356
P1476
Effect of Rosiglitazone on the ...... ath from Cardiovascular Causes
@en
P2093
Kathy Wolski
Steven E. Nissen
P304
P3181
P356
10.1056/NEJMOA072761
P407
P577
2007-06-14T00:00:00Z